Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protara Therapeutics, Inc. Director's Dealing 2022

Jul 5, 2022

34057_dirs_2022-07-05_eba667a5-e79b-4ad7-85d3-977989f1fe1e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2022-07-01

Reporting Person: Bandari Jathin (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-07-01 Common Stock F 682 $3.22 Disposed 20318 Direct

Footnotes

F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on July 1, 2020.